Tag: Subpotency

Affecting millions with hypothyroidism, the stability of levothyroxine is critical for patient health. A primary reason for recent instances where patients asked, 'Why was there a recall on levothyroxine?' relates to the medication's sensitive nature, which can cause its active ingredient to degrade over time, a problem known as subpotency.

In July 2025, the U.S. Food and Drug Administration (FDA) upgraded a significant recall involving more than 160,000 bottles of Levothyroxine Sodium, clarifying the answer to the question, "**What thyroid medicine is being recalled?**". This was classified as a Class II recall, indicating the product may cause temporary or medically reversible adverse health consequences.

As of September 2025, there are active recalls for specific batches of levothyroxine sodium tablets, with actions taken by manufacturers like Accord Healthcare and Pfizer. These recalls primarily cite subpotency, meaning the medication's active ingredient is below the labeled specification.